Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)

Avalo Therapeutics filings provide 8 years of Cost of Revenue readings, the most recent being $714000.0 for Q3 2024.

  • On a quarterly basis, Cost of Revenue rose 189.07% to $714000.0 in Q3 2024 year-over-year; TTM through Jun 2025 was $1.1 million, a 153.23% increase, with the full-year FY2023 number at $1.3 million, down 62.61% from a year prior.
  • Cost of Revenue hit $714000.0 in Q3 2024 for Avalo Therapeutics, up from $343000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.6 million in Q2 2022 to a low of -$221000.0 in Q4 2023.
  • Median Cost of Revenue over the past 5 years was $528000.0 (2022), compared with a mean of $483842.1.
  • Biggest five-year swings in Cost of Revenue: surged 1787.95% in 2022 and later plummeted 135.65% in 2023.
  • Avalo Therapeutics' Cost of Revenue stood at $79000.0 in 2020, then surged by 436.71% to $424000.0 in 2021, then surged by 46.23% to $620000.0 in 2022, then plummeted by 135.65% to -$221000.0 in 2023, then skyrocketed by 423.08% to $714000.0 in 2024.
  • The last three reported values for Cost of Revenue were $714000.0 (Q3 2024), $343000.0 (Q2 2024), and $80000.0 (Q1 2024) per Business Quant data.